---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-112644"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:29:58.753701+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model

## Summary
- Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.
- Neurological assessments found no adverse effects on attitude, behavior, or motor function.
- Company preparing for pre-IND meeting with FDA; advancing CMC scale-up and dose-ranging studies.
- Data support design of first-in-human Phase 1 clinical trial for INM-901.

## SEC filing metadata
- accession: 0001213900-25-112644
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025112644/0001213900-25-112644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025112644/ea0266453-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-112644
- JSON: https://secwatch.observer/filing/0001213900-25-112644.json
- Plain text: https://secwatch.observer/filing/0001213900-25-112644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.